Skip to Main Content

Paper Details

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
Cancer Med
18
2023
Author NameAffiliation
Martijn P LolkemaErasmus MC Cancer Institute
Emile E VoestNetherlands Cancer Institute
Emile E VoestOncode Institute
Michiel S van der HeijdenNetherlands Cancer Institute
  • 1 - 4

Datasets

Release 1.2